{"id":"W4229458082","doi":"10.1016/s2352-3026(22)00103-x","title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Celgene; European Hematology Association; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Transplantation; Autologous stem-cell transplantation; Oncology; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005212016,0.0002039816,0.0009657596,0.0001502723,0.0002874887,0.00002877116,0.0002808385,0.000052271,0.0001422771],"category_scores_gemma":[0.0003986575,0.0001374149,0.00003858393,0.0002064307,0.000104848,0.0001407392,0.0001043679,0.0001648425,0.000004127556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007542881,"about_ca_system_score_gemma":0.0001227297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003957418,"about_ca_topic_score_gemma":0.0002598267,"domain_scores_codex":[0.9979463,0.000460124,0.0004129523,0.0003946743,0.0003395819,0.000446337],"domain_scores_gemma":[0.9977651,0.001269636,0.0002112329,0.0004037087,0.0001403691,0.0002100116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9679289,0.004497272,0.008685218,0.000242145,0.000320776,0.0001796847,0.001285337,0.0000438441,0.000739986,0.0002614363,0.0008559143,0.01495949],"study_design_scores_gemma":[0.9783733,0.0110078,0.005724841,0.0000679585,0.0003656862,0.0001442358,0.0003361411,0.001123937,0.001598441,0.00008632469,0.000997043,0.0001742967],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876368,0.0001164402,0.000917935,0.0007316548,0.00009920194,0.009351031,0.001037044,0.00003416998,0.00007571936],"genre_scores_gemma":[0.9876275,0.00008503209,0.006399468,0.0003662432,0.00007536919,0.003737974,0.001627523,0.00003574935,0.00004515683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01478519,"threshold_uncertainty_score":0.5603618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06225182672412834,"score_gpt":0.3657000429541173,"score_spread":0.303448216229989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}